Intratumoral Hyperthermic Chemotherapy Injection in Peripheral Non-Small Cell Lung Cancer; Efficacy and Safety

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201702001974160

Enrollment

Registered

2017-01-15

Start date

2017-01-25

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer lung cancer

Interventions

hyperthermic chemotherapeutic agent

normothermic chemotherapeutic agen

systemic cemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with peripheral lung cancer planned to be treated by chemotherapy who include all of the following: 1- Histologically-diagnosed, peripheral NSCLC. 2- Patients who are not candidate for surgical treatment because of poor cardiopulmonary status, inoperable advanced stage of lung cancer or refusal of surgery 3- The patients are fit for chemotherapy with adequate bone marrow reserve: ¿ White blood cell count >3500/mm3. ¿ Neutrophil count >1800/mm3. ¿ Hemoglobin >10 gm /dL. ¿ Haematocrit value >30%

Exclusion criteria

Exclusion criteria: Patients with one or more of the following will be excluded: 1. Patient is operable and planned for surgery. 2. Tumors infiltrating the main stem bronchi, trachea and/or mediastinum as detected by fiberoptic bronchoscopy (FOB) and or CT chest (central bronchogenic carcinoma). 3. Uncooperative patients. 4. Patient with uncorrectable bleeding diathesis. 5. Lung cancer other than NSCLC (small cell lung cancer, metastatic lung cancer, lymphoma, sarcoma, others ). 6. Platelet count ¿ 50,000 mm3 and/or prothrombin time ¿ 50%. 7. Serum bilirubin more than 2.5 mg/dL, ALT and AST > 3 times normal level and creatinine > 1.5 mg/dL. 8. Patient with severe pulmonary dysfunction. 9. Patient with uncompensated cardiac comorbidities. 10. Hypersensitivity to cisplatin.

Design outcomes

Primary

Measure	Time frame
A. Clinical evaluation: It depends on recording the changes in patients¿ symptoms, performance status, and quality of life. B. Radiological evaluation will be done by: Chest X-ray and CT of the chest. C. Histopathological examination by tru cut biopsy after 6 months.	—

Secondary

Measure	Time frame
survival	—

Countries

Egypt

Contacts

Public Contactmohamed adel mohamed tohlob

assistant lecturer of Chest medicine ,faculty of medicine , Mansoura university

dr_mohamedtohlob@mans.edu.eg01112300281

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026